Viking Therapeutics Prices Upsized $500M Dual Capital Raise
Viking Therapeutics priced an upsized $500M capital raise, pairing $275M in common stock at $35 and $225M in 2% convertible senior notes due 2032.
GLP-1
The Ozempic Effect: How GLP-1 Drugs Are Reshaping Retail Stocks
Millions are losing weight on GLP-1s and refreshing their wardrobes. Wall Street is only beginning to price what this means for retail stocks.